Determining whether your product is a veterinary health product or drug in Canada is one of the first and most consequential decisions you will make before entering the market. Get this classification wrong, and you risk rejected submissions, forced product recalls, and months of lost time that your leadership team will not easily forgive.
The regulatory pathway for each category differs significantly in terms of documentation, timelines, and oversight. Understanding those differences early gives you a clear route to market and keeps your launch on schedule. This guide breaks down exactly how Health Canada distinguishes between the two categories, what criteria your product must meet, and where classification grey areas tend to trip teams up.
What Defines a Veterinary Health Product in Canada
Health Canada created the Veterinary Health Products (VHP) category to provide a streamlined regulatory pathway for low-risk health products intended for animal use. These products contain substances found on the List of Acceptable Non-prescription Veterinary Health Product Substances maintained by Health Canada. They do not require a Drug Identification Number (DIN) before sale.
A VHP must meet specific conditions. It must be for use in animals only, make limited health claims, and contain only substances from the approved list at acceptable doses. The claims you make on your label and marketing materials play a direct role in classification. Broad therapeutic claims push a product toward drug status, even if the ingredients themselves qualify for VHP listing.
Additionally, a VHP requires a notification submission rather than a full drug application. This process is faster, but it does not excuse you from meeting Good Manufacturing Practices (GMP) or labelling requirements. Health Canada can audit your product at any time post-market.
When Health Canada Classifies a Product as a Veterinary Drug
If your product does not meet all VHP criteria, Health Canada classifies it as a veterinary drug. This triggers a much more rigorous pre-market review. You must submit a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) and obtain a DIN before you can legally sell the product in Canada.
Several factors push a product into the drug classification. If your formulation includes an active ingredient not on the VHP approved substance list, it requires a drug submission. Similarly, if you intend to make claims about treating, preventing, or curing a specific disease, Health Canada treats the product as a drug regardless of its ingredients.
Prescription-only products always fall under drug classification. So do products intended for food-producing animals when they require withdrawal periods. The regulatory burden here is substantial. You should expect longer review timelines, more extensive safety and efficacy data requirements, and ongoing post-market obligations.
Key Differences Between the VHP and Drug Pathways
Understanding the practical differences between these two pathways helps you plan resources and timelines accurately. Below is a summary of the most significant distinctions.
- Pre-market authorization: VHPs require a notification to Health Canada. Drugs require a formal submission and DIN issuance before sale.
- Health claims: VHPs may make only low-risk, general health claims. Drugs may make specific therapeutic claims supported by clinical evidence.
- Ingredient restrictions: VHP ingredients must appear on the approved substance list. Drugs have no such list restriction but must demonstrate safety and efficacy through data.
- Review timelines: VHP notifications typically process within 30 days. Drug submissions can take months to years depending on the submission type and data package.
- Post-market requirements: Both categories must comply with GMP and adverse event reporting. Drugs carry additional pharmacovigilance obligations.
Common Classification Mistakes That Cause Delays
One of the most frequent errors regulatory teams make involves product claims. A product may contain only VHP-eligible ingredients, yet the marketing team drafts label claims that imply disease treatment. Health Canada evaluates the product as a whole, including its claims. Overstated claims can reclassify an otherwise straightforward VHP into a drug overnight.
Another common pitfall involves combination products. If your formulation mixes VHP-eligible substances with ingredients not on the approved list, the entire product defaults to drug classification. Teams sometimes overlook this when reformulating existing products or adapting formulations from other markets.
Failing to check the most current version of the approved substance list also creates problems. Health Canada updates this list periodically, and a substance that qualified last year may have changed conditions. Always verify your ingredients against the latest published list before submitting your notification.
How to Confirm Your Product’s Classification
Start by reviewing every active ingredient against Health Canada’s List of Acceptable Non-prescription Veterinary Health Product Substances. Confirm that each ingredient falls within the acceptable dose ranges specified. Then review your intended claims. If every ingredient qualifies and your claims remain within the low-risk category, you likely have a VHP.
If any doubt remains, document your rationale and seek a formal opinion. Health Canada’s Veterinary Drugs Directorate (VDD) can provide pre-submission guidance. However, this process takes time, so build it into your project timeline early. Regulatory consultants who specialize in veterinary product classification can also accelerate this step considerably.
Working with experienced professionals helps you avoid assumptions that lead to rejected submissions. Our team at Quality Smart Solutions has guided numerous companies through this exact classification process. You can contact our regulatory experts for a thorough assessment before you commit resources to the wrong pathway.
Frequently Asked Questions
Can I switch from a drug submission to a VHP notification if I change my product claims?
This is not always straightforward. Changing your claims alone does not automatically qualify a product as a VHP if the formulation still contains non-listed substances or requires prescription status. However, if you reformulate the product and align both the ingredients and the claims with VHP requirements, you may be eligible for the notification pathway. A classification review at that stage can confirm your options and save significant time.
Does a VHP notification guarantee my product will stay on the market?
No, a VHP notification does not provide the same level of regulatory protection as a DIN. Health Canada retains the authority to request additional information, require label changes, or remove a product from sale if it identifies safety concerns or non-compliance post-market. That said, companies that maintain GMP compliance and accurate labelling rarely encounter issues, and the VHP pathway remains one of the most efficient routes to market for qualifying products.
What happens if Health Canada disagrees with my self-assessed classification?
This scenario can cause significant delays, especially if you have already invested in manufacturing and packaging based on an incorrect classification. Health Canada may issue a notice requiring you to cease sales, relabel, or submit a full drug application. To avoid this outcome, many companies invest in professional classification reviews before submission. This upfront step protects your timeline and prevents costly rework down the line.
Key Takeaways
- Classification as a veterinary health product or drug depends on your product’s ingredients, intended claims, and target animal population.
- VHPs follow a faster notification pathway, but every ingredient must appear on Health Canada’s approved substance list at acceptable doses.
- Overstated health claims can push an otherwise VHP-eligible product into drug classification, adding months or years to your timeline.
- Always verify ingredients against the most current version of the approved substance list before preparing your submission.
- Engaging regulatory specialists early in the process reduces classification risk and keeps your product launch on track.
Bring Your Veterinary Product to Market with Confidence
Correctly classifying your product as a veterinary health product or drug from the outset protects your timeline, your budget, and your reputation within the organization. The distinction carries real consequences for how quickly you reach the Canadian market and how much regulatory effort you need to invest along the way.
Our team at Quality Smart Solutions specializes in veterinary product regulatory compliance, from initial classification through submission and post-market support. We help you build a clear, defensible regulatory strategy so your product reaches the market without unnecessary setbacks. Reach out to our regulatory compliance consultants to discuss your product classification and next steps.
